Xenon Pharmaceuticals Inc. Balance Sheet
XENE / Health Care|14 years of annual SEC 10-K data (FY2012-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 14 fiscal years. All figures from audited SEC 10-K filings.
Xenon Pharmaceuticals Inc. had $633M in total assets and $582M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $199.2M | $142.7M | $148.6M | $57.2M | $175.7M | $45.0M | $24.8M | $67.8M | $17.1M | $17.1M | $58.7M | $60.2M | $38.0M | $60.2M |
| Accounts Receivable | - | $1.5M | $874.0K | $986.0K | $2.8M | $1.8M | $813.0K | $151.0K | $438.0K | $200.0K | $315.0K | $215.0K | $440.0K | - |
| Current Assets | $560.6M | $635.3M | $645.0M | $600.3M | $559.0M | $181.8M | $144.9M | $121.3M | $44.8M | $65.7M | $60.9M | $84.9M | $49.9M | - |
| PP&E (Net) | $8.7M | $10.3M | $9.7M | $6.5M | $4.5M | $3.6M | $1.7M | $991.0K | $1.1M | $1.4M | $2.0M | $2.5M | $1.9M | - |
| Total Assets | $633.2M | $798.1M | $964.8M | $754.1M | $572.0M | $189.2M | $147.7M | $122.4M | $46.1M | $67.5M | $63.9M | $87.4M | $54.5M | - |
| Current Liabilities | $41.8M | $35.6M | $27.3M | $22.7M | $14.3M | $14.8M | $43.4M | $4.1M | $4.1M | $3.6M | $2.8M | $14.3M | $18.2M | - |
| Total Debt | - | - | - | - | - | - | $10.9M | $15.0M | $6.1M | - | - | - | - | - |
| Shareholders' Equity | $581.8M | $754.9M | $927.9M | $721.5M | $550.0M | $171.4M | $92.0M | $103.3M | $63.9M | $63.9M | $61.0M | -$89.9M | -$78.4M | -$89.9M |